These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

388 related articles for article (PubMed ID: 38627557)

  • 1. Combinatorial strategies to target RAS-driven cancers.
    Perurena N; Situ L; Cichowski K
    Nat Rev Cancer; 2024 May; 24(5):316-337. PubMed ID: 38627557
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Finding the sweet spot: Targeting RAS in tumors while sparing normal tissue.
    Perurena N; Cichowski K
    Cancer Cell; 2024 Jun; 42(6):943-945. PubMed ID: 38861932
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ras and exosome signaling.
    Sexton RE; Mpilla G; Kim S; Philip PA; Azmi AS
    Semin Cancer Biol; 2019 Feb; 54():131-137. PubMed ID: 30769101
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ras proteins as therapeutic targets.
    Chakraborty A; Linnane E; Ross S
    Biochem Soc Trans; 2018 Oct; 46(5):1303-1311. PubMed ID: 30154091
    [TBL] [Abstract][Full Text] [Related]  

  • 5. KRAS: From undruggable to a druggable Cancer Target.
    Uprety D; Adjei AA
    Cancer Treat Rev; 2020 Sep; 89():102070. PubMed ID: 32711246
    [TBL] [Abstract][Full Text] [Related]  

  • 6. RAS-targeted therapies: is the undruggable drugged?
    Moore AR; Rosenberg SC; McCormick F; Malek S
    Nat Rev Drug Discov; 2020 Aug; 19(8):533-552. PubMed ID: 32528145
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Improving Prospects for Targeting RAS.
    Singh H; Longo DL; Chabner BA
    J Clin Oncol; 2015 Nov; 33(31):3650-9. PubMed ID: 26371146
    [TBL] [Abstract][Full Text] [Related]  

  • 8. KRAS: A Promising Therapeutic Target for Cancer Treatment.
    Wu HZ; Xiao JQ; Xiao SS; Cheng Y
    Curr Top Med Chem; 2019; 19(23):2081-2097. PubMed ID: 31486755
    [TBL] [Abstract][Full Text] [Related]  

  • 9. RAS Function in cancer cells: translating membrane biology and biochemistry into new therapeutics.
    Kattan WE; Hancock JF
    Biochem J; 2020 Aug; 477(15):2893-2919. PubMed ID: 32797215
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Small-Molecule Inhibitors and Degraders Targeting KRAS-Driven Cancers.
    Hyun S; Shin D
    Int J Mol Sci; 2021 Nov; 22(22):. PubMed ID: 34830024
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic implications of RAS alterations in diverse malignancies and impact of targeted therapies.
    Kato S; Okamura R; Sicklick JK; Daniels GA; Hong DS; Goodman A; Weihe E; Lee S; Khalid N; Collier R; Mareboina M; Riviere P; Whitchurch TJ; Fanta PT; Lippman SM; Kurzrock R
    Int J Cancer; 2020 Jun; 146(12):3450-3460. PubMed ID: 31782524
    [TBL] [Abstract][Full Text] [Related]  

  • 12. KRAS and BRAF: drug targets and predictive biomarkers.
    Vakiani E; Solit DB
    J Pathol; 2011 Jan; 223(2):219-29. PubMed ID: 21125676
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Exploiting RAS Nucleotide Cycling as a Strategy for Drugging RAS-Driven Cancers.
    Mattox TE; Chen X; Maxuitenko YY; Keeton AB; Piazza GA
    Int J Mol Sci; 2019 Dec; 21(1):. PubMed ID: 31878223
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Therapeutic strategies to target RAS-mutant cancers.
    Ryan MB; Corcoran RB
    Nat Rev Clin Oncol; 2018 Nov; 15(11):709-720. PubMed ID: 30275515
    [TBL] [Abstract][Full Text] [Related]  

  • 15. KRAS-mutant colon cancer cells respond to combined treatment of ABT263 and axitinib.
    Wang G; Huang Y; Wu Z; Zhao C; Cong H; Ju S; Wang X
    Biosci Rep; 2019 Mar; 39(3):. PubMed ID: 30674639
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeting cytokine networks in KRAS-driven tumorigenesis.
    Golay HG; Barbie DA
    Expert Rev Anticancer Ther; 2014 Aug; 14(8):869-71. PubMed ID: 24928447
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeting Mutant KRAS for Anticancer Therapy.
    Chen F; Alphonse MP; Liu Y; Liu Q
    Curr Top Med Chem; 2019; 19(23):2098-2113. PubMed ID: 31475898
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inhibitors of K-Ras plasma membrane localization.
    Cho KJ; van der Hoeven D; Hancock JF
    Enzymes; 2013; 33 Pt A():249-65. PubMed ID: 25033808
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Drugging the Undruggable: Advances on RAS Targeting in Cancer.
    Molina-Arcas M; Samani A; Downward J
    Genes (Basel); 2021 Jun; 12(6):. PubMed ID: 34200676
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Oncogenic KRAS blockade therapy: renewed enthusiasm and persistent challenges.
    Tang D; Kroemer G; Kang R
    Mol Cancer; 2021 Oct; 20(1):128. PubMed ID: 34607583
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.